Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

411 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity.
Kim R, Emi M, Tanabe K. Kim R, et al. Among authors: emi m. Immunology. 2006 Oct;119(2):254-64. doi: 10.1111/j.1365-2567.2006.02430.x. Immunology. 2006. PMID: 17005005 Free PMC article. Review.
Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Kim R, et al. Among authors: emi m. Cancer Chemother Pharmacol. 2002 Nov;50(5):343-52. doi: 10.1007/s00280-002-0522-7. Epub 2002 Oct 3. Cancer Chemother Pharmacol. 2002. PMID: 12439591 Review.
Inducing cancer cell death by targeting transcription factors.
Kim R, Tanabe K, Emi M, Uchida Y, Inoue H, Toge T. Kim R, et al. Among authors: emi m. Anticancer Drugs. 2003 Jan;14(1):3-11. doi: 10.1097/00001813-200301000-00002. Anticancer Drugs. 2003. PMID: 12544253 Review.
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Tanabe K, et al. Among authors: emi m. Int J Oncol. 2003 Apr;22(4):875-81. Int J Oncol. 2003. PMID: 12632082
Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
Kim R, Tanabe K, Uchida Y, Emi M, Toge T. Kim R, et al. Among authors: emi m. Int J Mol Med. 2003 Jun;11(6):799-804. Int J Mol Med. 2003. PMID: 12736725
Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.
Kim R, Tanabe K, Emi M, Uchida Y, Toge T. Kim R, et al. Among authors: emi m. Oncol Rep. 2003 Nov-Dec;10(6):1925-30. Oncol Rep. 2003. PMID: 14534720
Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
Kim R, Tanabe K, Emi M, Uchida Y, Toge T. Kim R, et al. Among authors: emi m. Int J Oncol. 2004 Jan;24(1):5-17. Int J Oncol. 2004. PMID: 14654935 Review.
The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R, Emi M, Tanabe K, Uchida Y, Toge T. Kim R, et al. Among authors: emi m. Cancer. 2004 Jun 1;100(11):2281-91. doi: 10.1002/cncr.20270. Cancer. 2004. PMID: 15160330 Review.
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
Kim R, Emi M, Tanabe K, Toge T. Kim R, et al. Among authors: emi m. Cancer. 2004 Dec 1;101(11):2491-502. doi: 10.1002/cncr.20696. Cancer. 2004. PMID: 15503311 Review.
Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T. Kim R, et al. Among authors: emi m. Int J Oncol. 2005 Apr;26(4):1025-31. Int J Oncol. 2005. PMID: 15753998
411 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback